Unknown

Dataset Information

0

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.


ABSTRACT: The overall survival for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains low, with little progress made over decades. Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins. We have previously demonstrated that the pro-apoptotic BH3-only protein, NOXA plays a critical role in this process. NOXA binds and inactivates anti-apoptotic MCL-1, while the BCL-2 inhibitor ABT-263 is capable of inactivating anti-apoptotic BCL-2 and BCL-XL. We hypothesized that combination of NOXA and ABT-263 treatment increases cell death by simultaneously inhibiting anti-apoptotic BCL-2 family proteins in HNSCC cells. Here, we demonstrated that combination of ectopic NOXA expression and ABT-263 enhanced apoptosis in p53-inactive, p53 wild-type, and human papillomavirus (HPV)-positive HNSCC cell lines. Furthermore, a retinoid derivative and an endoplasmic reticulum stress inducer, fenretinide, induced NOXA, and combination of fenretinide and ABT-263 strongly induced apoptosis in HNSCC cells regardless of the HPV or p53 statuses. We also found that MCL-1 and BCL-XL are the primary targets of apoptosis induced by the combinations. These results will develop novel and alternative therapeutic strategies to directly modify the cell death machinery in HNSCC.

SUBMITTER: Britt EL 

PROVIDER: S-EPMC6611623 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.

Britt Erin L EL   Raman Sarina S   Leek Kendall K   Sheehy Casey H CH   Kim Sung W SW   Harada Hisashi H  

PloS one 20190705 7


The overall survival for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains low, with little progress made over decades. Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins. We have previously demonstrated that the pro-apoptotic BH3-only protein, NOXA plays a critical role in this process. NOXA binds and inactivates anti-apoptotic MCL-1, while the BCL-2 inhibitor ABT-263 is capable of inactiv  ...[more]

Similar Datasets

| S-EPMC2672802 | biostudies-other
| S-EPMC6496207 | biostudies-literature
| S-EPMC4364009 | biostudies-literature
| S-EPMC4694873 | biostudies-other
| S-EPMC9977433 | biostudies-literature
| S-EPMC3527691 | biostudies-literature
| S-EPMC3176271 | biostudies-other
| S-EPMC3553079 | biostudies-other
| S-EPMC6688996 | biostudies-literature
| S-EPMC3856035 | biostudies-literature